Kintara Therapeutics (KTRA)
(Delayed Data from NSDQ)
$0.19 USD
+0.02 (13.55%)
Updated Sep 17, 2024 03:59 PM ET
After-Market: $0.19 0.00 (-0.58%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
KTRA 0.19 +0.02(13.55%)
Will KTRA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for KTRA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for KTRA
Kintara (KTRA) Stock Soars on Merger Agreement With TuHURA
Kintara (KTRA) Rises 41% on $2M Grant for Breast Cancer Therapy
KTRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for KTRA
Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study
Kintara provides update on REM-001 clinical study
Kintara Therapeutics to Hold Special Meeting of Stockholders to Allow for Completion of the Proposed Merger with TuHURA Biosciences, Inc.
Kintara Therapeutics Announces Special Meeting for TuHURA Merger
Kintara Therapeutics: Clinical Trial Resumes Amid Merger Uncertainties